Dutch agrifood biotech’s €17 billion scale-up gap revised
Invest-NL’s scenario finds substantial potential additional revenue by 2040, with authorisation delays and first-factory funding blocking scale.
Better science does not automatically produce a commercial food ingredient or crop treatment. A Dutch agrifood biotech study identifies regulatory delays and first-factory finance as the gap between the two.
What happened
On 30 October, Invest-NL published a deep dive drawing on more than 150 interviews and fifteen years of investment data. Its scenario estimates around €17 billion in additional annual turnover by 2040 if companies can reach customers and scale more quickly.
The report covers areas including biological crop protection, climate-resilient crops and fermentation-derived proteins. It describes European crop-protection approvals taking eight to ten years and first factories costing tens or hundreds of millions of euros.
Why it matters
Those requirements can leave companies between venture funding and conventional project finance: too capital-intensive for a small equity round, but too early for lenders seeking predictable operations.
The report calls for coordinated approvals, testing access, earlier customer involvement and public capital to share industrialisation risk.
The bigger picture
The €17 billion figure is a conditional scenario, rather than current sales or a funding commitment. Its central point is practical: capturing the opportunity requires financing commercial production, alongside funding laboratory development.